Apollomics (APLM) vs Connect Biopharma (CNTB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Apollomics (APLM) has outperformed Connect Biopharma (CNTB) over the past year, gaining 16.6% versus a loss of 46.9%. Apollomics is the larger company by market cap ($66.0 million vs $59.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APLM | CNTB |
|---|---|---|
| Share price | $22.65 | $0.9371 |
| Market cap | $66.02M | $59.01M |
| 1-day change | +5.35% | -0.80% |
| YTD return | +15.00% | -66.50% |
| 1-year return | +16.64% | -46.93% |
| 5-year return | — | -94.50% |
| EPS (TTM) | $-7.57 | $-1.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $42.12 | $3.82 |
| 52-week low | $10.01 | $0.85 |
| Distance from 52-week high | -46.23% | -75.47% |
| Average volume | 21.61K | 3.83M |
| Shares outstanding | 2.91M | 62.97M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- APLM has outperformed CNTB by 63.6 percentage points over the past year.
APLM vs CNTB FAQ
Which is bigger, Apollomics or Connect Biopharma?
Apollomics (APLM) is larger, with a market capitalization of $66.02M compared with $59.01M for Connect Biopharma (CNTB).
Which stock has performed better over the past year, APLM or CNTB?
APLM returned +16.64% over the past 12 months, compared with -46.93% for CNTB (price return, excluding dividends). Past performance does not predict future results.
Are Apollomics and Connect Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.